Smith & Nephew (NYSE:SNN) Lowered to “Buy” Rating by StockNews.com

StockNews.com downgraded shares of Smith & Nephew (NYSE:SNN) from a strong-buy rating to a buy rating in a report issued on Tuesday.

Several other equities analysts have also commented on SNN. Deutsche Bank Aktiengesellschaft lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Berenberg Bank lowered shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

Smith & Nephew Stock Up 0.1 %

SNN opened at $24.64 on Tuesday. Smith & Nephew has a 52 week low of $23.65 and a 52 week high of $31.72. The stock’s fifty day moving average is $29.00 and its two-hundred day moving average is $27.84. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51.

Institutional Investors Weigh In On Smith & Nephew

A number of hedge funds have recently made changes to their positions in SNN. Maverick Capital Ltd. purchased a new position in Smith & Nephew in the third quarter valued at about $2,086,000. Hantz Financial Services Inc. boosted its holdings in shares of Smith & Nephew by 14.3% in the 3rd quarter. Hantz Financial Services Inc. now owns 71,437 shares of the medical equipment provider’s stock valued at $2,225,000 after buying an additional 8,917 shares in the last quarter. Townsquare Capital LLC grew its position in shares of Smith & Nephew by 5.4% in the 3rd quarter. Townsquare Capital LLC now owns 14,759 shares of the medical equipment provider’s stock worth $460,000 after buying an additional 761 shares during the last quarter. Cerity Partners LLC raised its stake in shares of Smith & Nephew by 31.5% during the 3rd quarter. Cerity Partners LLC now owns 19,001 shares of the medical equipment provider’s stock worth $592,000 after acquiring an additional 4,552 shares in the last quarter. Finally, Citigroup Inc. lifted its position in Smith & Nephew by 18.5% during the third quarter. Citigroup Inc. now owns 119,215 shares of the medical equipment provider’s stock valued at $3,712,000 after acquiring an additional 18,630 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.